Tandem Diabetes Care Announces Fourth Quarter and Full Year 2019 Financial Results and 2020 Financial Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
Tandem Diabetes (TNDM) Tops Q4 EPS by 9c, Revenues Miss; Offers FY20 Revenue Guidance Above Consensus
February 24, 2020 4:11 PM ESTTandem Diabetes (NASDAQ: TNDM) reported Q4 EPS of $0.04, $0.09 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $108.4 million versus the consensus estimate of $109.22 million.
In comparing the fourth quarter of 2019 to the same period of 2018:
Worldwide pump shipments increased 21 percent to 19,602 pumps from 16,168 pumpsSales increased 42 percent to $108.4 million from $76.2 millionGross margin improved 1 point to 56 percent of sales... More